Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd ...

Evolus Inc . (NASDAQ:EOLS), a company specializing in aesthetic products with a market capitalization of $933 million, has recently made significant strides in expanding its product portfolio and ...

HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS – Free Report) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $27.00 price ...

Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.

Evolus, Inc. EOLS shares rallied 5.5% in the last trading session to close at $15.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ ...

During the last three months, 4 analysts shared their evaluations of Evolus EOLS, revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings ...

Evolus (EOLS) announced that the Food and Drug Administration has approved Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels, ...

EST Evolus (EOLS) trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart ...